ET in combination with CDK4/6 inhibitors (CDK4/6i) has become the standard-of-care for first- or second-line treatment of ER-positive/HER2-negative ABC, due to their efficacy results, toxicity profile and quality of life data [I, A]. This evidence concerns the gene ESR1 and aneurysmal bone cyst.